Hepatocellular Carcinoma Clinical Trial
Official title:
REgistry of Selective Internal Radiation Therapy in TaiwaN (RESIN)
All study objectives will be assessed in HCC patients or colorectal cancer patients with secondary metastases in the liver, respectively.
All study objectives will be assessed in HCC patients or colorectal cancer patients with
secondary metastases in the liver, respectively.
1. Primary objective:
- To observe the safety of SIR-Spheres® microspheres therapy (SIRT)by,
- Adverse events and serious adverse events (non-specific and radiation
specific)
- Changes in liver function parameters
- To observe the efficacy of SIR-Spheres® microspheres therapy by, assessing the best
overall response rate after SIRT
2. Secondary objectives:
- To observe the efficacy of SIRT by,
- Overall survival (OS)
- Overall/objective response rate (ORR)
- Time-to-progression
- Time-to-liver progression
- Progression-free survival
- To observe the changes in clinical presentation after SIRT by,
- ECOG score
- Child-Pugh score
- Percentage of subjects with down-staging or down-sizing of treated lesion to
resection, transplantation, or radiofrequency ablation (RFA)
- To observe the practice pattern of SIRT by,
- Median dosage (GBq)
- Number of SIRT sessions received by subjects
3. Exploratory objectives:
- To explore prognostic factors for disease progression after SIRT by comparing the
following parameters:
- Number of tumors in subjects prior to SIRT
- Median tumor size in subjects prior to SIRT
- Location of tumor in subjects treated with SIRT (hepatic segment or lobe)
- Number of prior TACE treatment in subjects
- Antiviral therapy subjects HCC
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |